MKI67 and neoplasm: Statistically significant associations were found with the use of NAT in terms of age (median age 50.4 years in NAT patients vs. 62.4 years in surgical patients; p < 0.001), premenopausal status (54.5% vs. 28.7%; p < 0.001), clinical tumor size > 2 cm (87% vs. 24.8%; p < 0.001), positive clinical nodal status (55.9% vs. 21.4%; p < 0.001), grading G3 (61.7% vs. 25.2%; p < 0.001), Ki-67 value ≥ 20% (62.8% vs. 40.3%; p < 0.001).